Raf protein kinase therapeutics
    1.
    发明授权
    Raf protein kinase therapeutics 失效
    Raf蛋白激酶治疗

    公开(公告)号:US06689560B1

    公开(公告)日:2004-02-10

    申请号:US08207954

    申请日:1994-03-18

    IPC分类号: C12Q168

    摘要: It is a general object of this invention to provide a DNA segment comprising a Raf gene in an antisense orientation downstream of a promoter. It is a specific object of this invention to provide a method of inhibiting Raf expression comprising expressing an antisense Raf gene in a cell such that said Raf expression is inhibited. It is a further object of the invention to provide a method of inhibiting Raf kinase activity comprising replacement of a serine or threonine amino acid within the Raf gene for a non-phosphorylated amino acid.

    摘要翻译: 本发明的一般目的是提供一种包含在启动子下游的反义方向的Raf基因的DNA区段。 本发明的具体目的是提供抑制Raf表达的方法,包括在细胞中表达反义Raf基因,使得所述Raf表达被抑制。 本发明的另一个目的是提供一种抑制Raf激酶活性的方法,包括在非磷酸化氨基酸的Raf基因内替换丝氨酸或苏氨酸氨基酸。

    Detection method for c-raf-1 genes
    2.
    发明授权
    Detection method for c-raf-1 genes 失效
    c-raf-1基因检测方法

    公开(公告)号:US5618670A

    公开(公告)日:1997-04-08

    申请号:US185282

    申请日:1994-01-24

    摘要: The present invention relates to (1) a method of identifying an individual at an increased risk for developing cancer, (2) a method for determining a prognosis in patients afflicted with cancer, and (3) a method for determining the proper course of treatment for a patient afflicted with cancer; comprising: amplifying a region of the c-raf-1 gene.

    摘要翻译: 本发明涉及(1)识别发生癌症风险增加的个体的方法,(2)确定患有癌症的患者的预后的方法,以及(3)确定适当治疗过程的方法 对于患有癌症的患者; 包括:扩增c-raf-1基因的区域。

    Detection method for C-RAF-1 genes
    3.
    发明授权
    Detection method for C-RAF-1 genes 失效
    C-RAF-1基因检测方法

    公开(公告)号:US5869308A

    公开(公告)日:1999-02-09

    申请号:US831317

    申请日:1997-04-01

    摘要: The present invention relates to (1) a method of identifying an individual at an increased risk for developing cancer, (2) a method for determining a prognosis in patients afflicted with cancer, and (3) a method for determining the proper course of treatment for a patient afflicted with cancer; comprising: amplifying a region of the c-raf-1 gene.

    摘要翻译: 本发明涉及(1)识别发生癌症风险增加的个体的方法,(2)确定患有癌症的患者的预后的方法,以及(3)确定适当治疗过程的方法 对于患有癌症的患者; 包括:扩增c-raf-1基因的区域。

    Identification of biomarkers for liver toxicity
    4.
    发明授权
    Identification of biomarkers for liver toxicity 有权
    鉴定肝毒性的生物标志物

    公开(公告)号:US07452678B2

    公开(公告)日:2008-11-18

    申请号:US10873595

    申请日:2004-06-22

    IPC分类号: G01N33/53

    CPC分类号: G01N33/5014 G01N33/576

    摘要: The present invention relates to biomarker polypeptides, polynucleotides, and antibodies that have utility in predicting in vitro and/or in vivo hepatotoxicity of various drugs, compounds, or other therapeutic agents (i.e., test substances). Also related are screens, kits, microarrays, and cell culture systems that employ the polypeptides, polynucleotides, and/or antibodies of the invention. The reagents and methods of the invention are useful for predicting hepatotoxic effects resulting from treatment with one or more test substances, and can be utilized before, after, or concurrently with pre-clinical, clinical, and/or post-clinical testing. In this way, the reagents and methods of the invention can be used to identify test substances or combinations of test substances that cause hepatic injury, including idiosyncratic hepatotoxicity, and thereby prevent medical complications (e.g., liver failure) resulting from such injury.

    摘要翻译: 本发明涉及可用于预测各种药物,化合物或其它治疗剂(即测试物质)的体外和/或体内肝毒性的生物标记多肽,多核苷酸和抗体。 还涉及使用本发明的多肽,多核苷酸和/或抗体的筛选,试剂盒,微阵列和细胞培养系统。 本发明的试剂和方法可用于预测用一种或多种测试物质治疗产生的肝毒性作用,并且可以在临床前,临床和/或临床后测试之前,之后或同时使用。 以这种方式,本发明的试剂和方法可以用于鉴定引起肝损伤(包括特异性肝毒性)的测试物质或测试物质的组合,从而防止由于这种损伤引起的医疗并发症(例如肝衰竭)。